As cancers progress, they produce a local environment that acts to redirect, paralyze, exhaust, or otherwise evade immune detection and destruction. The tumor microenvironment (TME) has long been characterized as a metabolic desert, depleted of essential nutrients such as glucose, oxygen, and amino acids, that starves infiltrating immune cells and renders them dysfunctional. While not incorrect, this perspective is only half the picture. The TME is not a metabolic vacuum, only consuming essential nutrients and never producing by-products. Rather, the by-products of depleted nutrients, “toxic” metabolites in the TME such as lactic acid, kynurenine, ROS, and adenosine, play an important role in shaping immune cell function and cannot be overlooked in cancer immunotherapy. Moreover, while the metabolic landscape is distinct, it is not unique, as these toxic metabolites are encountered in non-tumor tissues, where they evolutionarily shape immune cells and their response. In this Review, we discuss how depletion of essential nutrients and production of toxic metabolites shape the immune response within the TME and how toxic metabolites can be targeted to improve current cancer immunotherapies.
McLane J. Watson, Greg M. Delgoffe
Title and authors | Publication | Year |
---|---|---|
Lactate and lactylation in cancer
Chen J, Huang Z, Chen Y, Tian H, Chai P, Shen Y, Yao Y, Xu S, Ge S, Jia R |
Signal Transduction and Targeted Therapy | 2025 |
Reprogramming of Glucose Metabolism by Nanocarriers to Improve Cancer Immunotherapy: Recent Advances and Applications
Jiang K, Liu H, Chen X, Wang Z, Wang X, Gu X, Tong Y, Ba X, He Y, Wu J, Deng W, Wang Q, Tang K |
International Journal of Nanomedicine | 2025 |
Tumour interstitial fluid-enriched phosphoethanolamine suppresses T cell function.
Wang Y, Wilfahrt D, Jonker P, Lontos K, Cai C, Cameron B, Xie B, Peralta RM, Schoedel ER, Gunn WG, AminiTabrizi R, Shah H, Rivadeneira DB, Muir A, Delgoffe GM |
Nature cell biology | 2025 |
The integrated single-cell analysis interpret the lactate metabolism-driven immune suppression in triple-negative breast cancer.
Gao X, Wang T, Liu C, Li Y, Zhang W, Zhang M, Yao Y, Gao C, Liu R, Sun C |
Discover oncology | 2025 |
Characterization of the aryl hydrocarbon receptor as a potential candidate to improve cancer T cell therapies.
De Castro V, Abdellaoui O, Dehecq B, Ndao B, Mercier-Letondal P, Dauvé A, Garnache-Ottou F, Adotévi O, Loyon R, Godet Y |
Cancer immunology, immunotherapy : CII | 2025 |
Integrated longitudinal multi-omics study identifies immune programs associated with COVID-19 severity and mortality in 1152 hospitalized participants
Jeremy Gygi, Cole Maguire, Ravi K. Patel, Pramod Shinde, Anna Konstorum, Casey Shannon, Leqi Xu, Annmarie Hoch, Naresh Jayavelu, Elias Haddad, Elaine Reed, Monica Kraft, Grace McComsey, Jordan Metcalf, Al Ozonoff, Denise Esserman, Charles Cairns, Nadine Rouphael, Steven Bosinger, Seunghee Kim-Schulze, Florian Krammer, Lindsey Rosen, Harm Bakel, Michael R. Wilson, Walter Eckalbar, Holden Maecker, Charles Langelier, Hanno Steen, Matthew C. Altman, Ruth R Montgomery, Ofer Levy, Esther Melamed, Bali Pulendran, Joann Diray-Arce, Kinga Smolen, Gabriela Fragiadakis, Patrice M. Becker, Alison Augustine, Rafick Sekaly, Lauren Ehrlich, Slim Fourati, Bjoern Peters, Steven H. Kleinstein, Leying Guan |
Journal of Clinical Investigation | 2024 |
Glycolysis Induced by METTL14 Is Essential for Macrophage Phagocytosis and Phenotype in Cervical Cancer
Wang B, Mao Z, Ye J, Jiao X, Zhang T, Wang Q, Han S, Zhang Y, Wang C, Dong T, Cui B |
2024 | |
CRISPR-Cas gene knockouts to optimize engineered T cells for cancer immunotherapy.
De Castro V, Galaine J, Loyon R, Godet Y |
Cancer Gene Therapy | 2024 |
Immunogenic cell death: A new strategy to enhancing cancer immunotherapy
Dou L, Fang Y, Yang H, Ai G, Shen N |
Human Vaccines & Immunotherapeutics | 2024 |
Aryl hydrocarbon receptor as a drug target in advanced prostate cancer therapy – obstacles and perspectives
Procházková J, Kahounová Z, Vondráček J, Souček K |
Transcription | 2024 |
Therapeutic targeting of tumour myeloid cells.
Barry ST, Gabrilovich DI, Sansom OJ, Campbell AD, Morton JP |
Nature reviews. Cancer | 2023 |
CDK4/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer.
Shrestha M, Wang DY, Ben-David Y, Zacksenhaus E |
Oncogenesis | 2023 |
Myeloid-derived suppressor cells impair CD4+ T cell responses during chronic Staphylococcus aureus infection via lactate metabolism
Goldmann O, Medina E |
Cellular and Molecular Life Sciences | 2023 |
Leveraging high-resolution omics data for predicting responses and adverse events to immune checkpoint inhibitors.
Limeta A, Gatto F, Herrgård MJ, Ji B, Nielsen J |
Computational and Structural Biotechnology Journal | 2023 |
Amino acid metabolism reprogramming: shedding new light on T cell anti-tumor immunity
Zheng Y, Yao Y, Ge T, Ge S, Jia R, Song X, Zhuang A |
Journal of experimental & clinical cancer research : CR | 2023 |
PDK4-dependent hypercatabolism and lactate production of senescent cells promotes cancer malignancy.
Dou X, Fu Q, Long Q, Liu S, Zou Y, Fu D, Xu Q, Jiang Z, Ren X, Zhang G, Wei X, Li Q, Campisi J, Zhao Y, Sun Y |
Nature metabolism | 2023 |
Itaconate promotes hepatocellular carcinoma progression by epigenetic induction of CD8+ T-cell exhaustion
Gu X, Wei H, Suo C, Shen S, Zhu C, Chen L, Yan K, Li Z, Bian Z, Zhang P, Yuan M, Yu Y, Du J, Zhang H, Sun L, Gao P |
Nature Communications | 2023 |
The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment
Kim SK, Cho SW |
Frontiers in pharmacology | 2022 |
Potential of mRNA vaccines to become versatile cancer vaccines.
Tsao SY |
World journal of clinical oncology | 2022 |
MITOCHONDRIA IN CANCER: CLEAN WINDMILLS OR STRESSED TINKERERS?
Altieri DC |
Trends in Cell Biology | 2022 |
Proton pump inhibitors display anti‐tumour potential in glioma
Li B, Liu Y, Sun S |
Cell Proliferation | 2022 |